In this analysis of the STEP 2 trial in people with type 2 diabetes, CRP levels were reduced with both semaglutide 2.4 mg and 1.0 mg versus placebo, with no significant difference between the semaglutide doses. The gene discussed is CRP; the disease is type 2 diabetes mellitus.